| __timestamp | Amneal Pharmaceuticals, Inc. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 60716000 |
| Thursday, January 1, 2015 | 109679000 | 119401000 |
| Friday, January 1, 2016 | 118757000 | 140879000 |
| Sunday, January 1, 2017 | 109046000 | 199243000 |
| Monday, January 1, 2018 | 230435000 | 240636000 |
| Tuesday, January 1, 2019 | 289598000 | 264359000 |
| Wednesday, January 1, 2020 | 326727000 | 260583000 |
| Friday, January 1, 2021 | 365504000 | 324951000 |
| Saturday, January 1, 2022 | 399700000 | 372766000 |
| Sunday, January 1, 2023 | 429675000 | 378378000 |
| Monday, January 1, 2024 | 396826000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical and biotechnology sectors, understanding the financial dynamics is crucial. Over the past decade, Bio-Techne Corporation and Amneal Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Amneal Pharmaceuticals saw a staggering 408% increase in SG&A expenses, peaking in 2023. This growth reflects their aggressive expansion and market penetration strategies. In contrast, Bio-Techne Corporation's SG&A expenses grew by approximately 523% over the same period, indicating a robust investment in operational efficiency and market presence.
Interestingly, while Amneal's expenses consistently rose, Bio-Techne experienced a slight dip in 2020, only to rebound strongly in subsequent years. This divergence highlights the different strategic approaches these companies have taken in navigating the ever-evolving healthcare landscape.
Johnson & Johnson or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Sanofi vs Bio-Techne Corporation
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Bio-Techne Corporation or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Bio-Techne Corporation vs CRISPR Therapeutics AG: SG&A Expense Trends
Bio-Techne Corporation or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or ImmunityBio, Inc.
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Wave Life Sciences Ltd.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Xencor, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs ImmunityBio, Inc.